{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:51:23Z","timestamp":1782449483305,"version":"3.54.5"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The PACIFIC regimen (consolidation durvalumab following chemoradiotherapy) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). With the publication of data from the phase III LAURA trial and the emergence of real-world evidence regarding sequential toxicity, concurrent chemoradiotherapy followed by sequential targeted therapy with EGFR tyrosine kinase inhibitors (TKIs) is recommended for patients with EGFR mutations. However, the optimal combination regimen remains to be determined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched the PubMed, Embase, Cochrane Library, and Web of Science databases to identify randomized controlled trials (RCTs) and high-quality retrospective studies comparing various therapeutic strategies for unresectable stage III EGFR-mutated NSCLC. The primary endpoints were progression-free survival (PFS) and overall survival (OS), while secondary endpoints included the objective response rate (ORR) and safety profiles. A network meta-analysis (NMA) was performed using a Bayesian random-effects model. Hazard ratios (HRs), odds ratios (ORs), and their corresponding 95% credible intervals (CrIs) were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 12 studies involving 1,529 patients were analyzed to compare six therapeutic strategies: consolidation durvalumab following chemoradiotherapy (CRT+Durva), CRT alone, consolidation EGFR-TKIs after CRT (CRT+EGFR-TKI), EGFR-TKI monotherapy, EGFR-TKI in combination with chemotherapy (EGFR-TKI+Chemo), and EGFR-TKI integrated with radiotherapy (EGFR-TKI+RT) via induction, concurrent, or consolidation sequencing. NMA revealed that CRT+EGFR-TKI was the only strategy to demonstrate a statistically significant improvement in OS compared to CRT alone (HR\u00a0=\u00a00.63, 95% CrI: 0.41\u20130.94), while also achieving the highest ORR. EGFR-TKI+RT (chemotherapy-free regimen) ranked first for PFS (HR\u00a0=\u00a00.14, 95% CrI: 0.06\u20130.33) and exhibited a favorable safety profile, associated with the lowest risk of severe radiation pneumonitis (RP). Notably, CRT+Durva failed to yield a survival benefit (PFS: HR\u00a0=\u00a00.75; OS: HR\u00a0=\u00a00.82) and was characterized by higher toxicity. An RCT-only sensitivity analysis demonstrated consistent PFS benefits and a comparable OS trend (HR\u00a0=\u00a00.68, 95% CrI: 0.33\u20131.4), validating the integration of real-world data to maintain adequate statistical power.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For unresectable stage III EGFR-mutated NSCLC, CRT+EGFR-TKI represents the optimal strategy for extending OS. Conversely, the EGFR-TKI+RT (chemotherapy-free regimen) approach provides a superior balance between prolonged PFS and clinical tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420261285935.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1852617","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:39:45Z","timestamp":1782448785000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimal treatment strategies for unresectable stage III EGFR-mutated non-small cell lung cancer: a systematic review and Bayesian network meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yang","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Oncology, Shaoyang Central Hospital","place":["Shaoyang, Hunan, China"]},{"name":"First Clinical Medical College, Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhan","family":"Sun","sequence":"additional","affiliation":[{"name":"First Clinical Medical College, Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine,Shaoyang Central Hospital","place":["Shaoyang, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shaoyang Central Hospital","place":["Shaoyang, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, General Hospital of Ningxia Medical University","place":["Yinchuan, Ningxia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2020.03.40","article-title":"Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival","volume":"10","author":"Casal-Mouri\u00f1o","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.02.009","article-title":"Brief report: Durvalumab after chemoradiotherapy in unresectable stage III EGFR-mutant NSCLC: A post hoc subgroup analysis from PACIFIC","volume":"18","author":"Naidoo","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1016\/j.jtho.2023.09.088","article-title":"OA17.03 Real-world outcomes with durvalumab after chemoradiotherapy in unresectable stage III EGFR-mutated NSCLC (PACIFIC-R)","volume":"18","author":"Peters","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12229","article-title":"The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation","volume":"41","author":"Ma","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218223","article-title":"Consensus on the diagnosis and treatment of unresectable stage III driver gene-positive non-small cell lung cancer","volume":"639","author":"Meng","year":"2026","journal-title":"Cancer Lett"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12611","article-title":"Exciting progress in targeted therapy innovation for unresectable stage III EGFR-mutated NSCLC: the phase III LAURA study","volume":"44","author":"Tong","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102918","article-title":"The evolving landscape of stage III unresectable non-small cell lung cancer \u201cbetween lights and shadows","volume":"135","author":"Delcuratolo","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jncc.2022.11.003","article-title":"Real-world treatment patterns and clinical outcomes in EGFR-mutant locally advanced lung adenocarcinoma: A multi-center cohort study","volume":"3","author":"Bi","year":"2023","journal-title":"J Natl Cancer Center"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1101\/2024.03.11.24304144","article-title":"Radiotherapy combined with EGFR-TKIs for stage III EGFR-mutated lung cancer: A retrospective cohort study","author":"Gang","year":"2024"},{"key":"B12","doi-asserted-by":"publisher","first-page":"102918","DOI":"10.1007\/s12325-025-03488-x","article-title":"Treatment patterns and clinical outcomes in unresectable stage III EGFR-mutated non-small cell lung cancer in China","volume":"43","author":"Lu","year":"2026","journal-title":"Adv Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"OP","DOI":"10.1200\/OP-25-01061","article-title":"Role of EGFR-TKIs in nonmetastatic epidermal growth factor receptor\u2013mutated non\u2013small cell lung cancer: A comprehensive review","author":"Delasos","year":"2026","journal-title":"JCO Oncol Pract"},{"key":"B14","doi-asserted-by":"publisher","first-page":"djag008","DOI":"10.1093\/jnci\/djag008","article-title":"Targeting common EGFR mutations in non\u2013small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors","author":"Melosky","year":"2026","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1038\/s43856-026-01505-w","article-title":"Assessment of pneumonitis in patients with lung cancer undergoing radioimmunotherapy and immune checkpoint inhibitor rechallenge","volume":"6","author":"Ruan","year":"2026","journal-title":"Commun Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12885-024-11946-y","article-title":"Radiation pneumonitis after concurrent aumolertinib and thoracic radiotherapy in EGFR-mutant non-small cell lung cancer patients","volume":"24","author":"Yin","year":"2024","journal-title":"BMC Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2024.04.012","article-title":"Interstitial pneumonitis following sequential administration of programmed death-1\/programmed death-ligand1 inhibitors and epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer: A matched\u2010pair cohort study using a nationwide inpatient database","volume":"25","author":"Iwai","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.021","article-title":"PL04.13 Aumolertinib maintenance after chemoradiotherapy in stage III non-small-cell lung cancer: Interim results of the phase III study (POLESTAR)","volume":"19","author":"Yu","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.12.015","article-title":"Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC\u2014an update from the PACIFIC trial","volume":"16","author":"Faivre-Finn","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.11.026","article-title":"Erlotinib versus etoposide\/cisplatin with radiation therapy in unresectable stage III epidermal growth factor receptor mutation-positive non-small cell lung cancer: A multicenter, randomized, open-label, phase 2 trial","volume":"109","author":"Xing","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B22","doi-asserted-by":"publisher","first-page":"8048","DOI":"10.1200\/JCO.2025.43.16_suppl.8048","article-title":"Survival of induction aumolertinib followed by aumolertinib and concurrent radiotherapy (RT) in unresectable EGFR-mutated stage III NSCLC: Final analysis of the phase III ADVANCE trial and real-world data","volume":"43","author":"Bi","year":"2025","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108597","article-title":"Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese real-world data analysis","volume":"205","author":"Fujisaki","year":"2025","journal-title":"Lung Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.01.012","article-title":"Consolidation osimertinib versus durvalumab versus observation after concurrent chemoradiation in unresectable EGFR-mutant NSCLC: A multicenter retrospective cohort study","volume":"19","author":"Nassar","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.18632\/aging.205425","article-title":"Treatment patterns and survival analysis in patients with unresectable stage III EGFR-mutated non-small cell lung cancer","volume":"16","author":"Liang","year":"2024","journal-title":"Aging (Albany NY)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14237","article-title":"Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors","volume":"13","author":"Wang","year":"2022","journal-title":"Thorac Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.1628","article-title":"Durvalumab for stage III EGFR-mutated NSCLC after definitive chemoradiotherapy","volume":"16","author":"Aredo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12847","article-title":"Comparative effectiveness of concurrent chemoradiotherapy versus EGFR-tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR","volume":"9","author":"Hsia","year":"2018","journal-title":"Thorac Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2147\/LCTT.S520833","article-title":"LAURA completes the osimertinib treatment jigsaw puzzle of EGFR+ NSCLC from stage IB to IV: Adjuvant osimertinib significantly improves PFS and CNS progression in unresectable stage III EGFR-mutated NSCLC compared to placebo (LAURA, NCT03521154)","volume":"16","author":"Luo","year":"2025","journal-title":"Lung Cancer (Auckland NZ)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/01.JTO.0000438438.14562.c8","article-title":"A multicenter, randomized, openlabel, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with activating mutation of epidermal growth factor receptor (EGFR) in exon 19 or 21(recel, ml28545, nct01714908)","volume":"8","author":"Xing","year":"2013","journal-title":"J Thorac Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.21037\/tlcr-24-751","article-title":"Clinical features and outcomes of unresectable locally advanced lung adenocarcinoma with uncommon EGFR mutations: a retrospective multi-center Chinese study","volume":"14","author":"Xu","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/curroncol32030146","article-title":"Lung cancer: Targeted therapy in 2025","volume":"32","author":"Bouchard","year":"2025","journal-title":"Curr Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1852617\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:39:56Z","timestamp":1782448796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1852617\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":32,"alternative-id":["10.3389\/fonc.2026.1852617"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1852617","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"article-number":"1852617"}}